RT Book, Section
A1 Guillem, José G.
A1 Ruby, Jeannine A.
A2 Zinner, Michael J.
A2 Ashley, Stanley W.
SR Print(0)
ID 57015811
T1 Chapter 38A. Perspective on Colonic Neoplasms
T2 Maingot's Abdominal Operations, 12e
YR 2013
FD 2013
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-163388-8
LK accesssurgery.mhmedical.com/content.aspx?aid=57015811
RD 2024/10/15
AB The  management  of  colorectal  cancer  has  progressed  over  the  past  two  decades  because  of  many  advances,  including  those  in  genetics,  pathology,  imaging,  medical  oncology,  radiation  oncology,  and  surgery.  Within  genetics,  a  number  of  mutations  have  been  identified  that  play  a  causative  role  in  colon  carcinogenesis  and  have  led  to  developments  in  targeted  therapies  and  genetic  testing  for  familial  syndromes.  Currently,  most  patients  presenting  with  an  inherited  form  of  colorectal  neoplasm  can  be  classified  as  having  adenomatous  (familial  adenomatous  polyposis  [FAP],  attenuated  FAP  [AFAP],  MUTYH-associated  polyposis  [MAP],  Lynch  syndrome,  and  familial  colorectal  cancer  type  X  [FCC  X])1  or  hamartomatous  [juvenile  polyposis  syndrome  [JPS]  and  Peutz-Jeghers  syndrome  [PJS])  polyps.  With  the  exception  of  FCC  X,  genetic  testing  can  now  diagnose  all  of  the  aforementioned  syndromes,  thereby  making  prophylactic  risk-reducing  surgery  a  practical  option.